Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 265

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 265
---
, we did not grant stock options to our named executive officers during any period beginning four business days before and ending one business day after the filing or furnishing of a Form 10-Q, 10-K or 8-K that discloses material nonpublic information. Stock Option Awards The Compensation Committee approved stock option awards to each of the then-serving executive officers in March 2024 following the completion of the Business Combination. In light of the decline in the Company’s stock price and financial condition, resulting in challenges with executive and employee retention, the extraordinary efforts required of the Company’s management team in connection with obtaining financing to remain viable and to cause the FDA to lift the clinical hold implemented in July 2024 and accept the submission of the IND in November 2024, the Compensation Committee approved the repricing of awards to executive officers and employees and the grants of new awards to new hires and executive officers who were internally promoted, in each case on October 1, 2024, with a substantial portion of the awards to executive officers containing performance-based vesting criteria, including with respect to the acceptance of the IND and obtaining additional financing. See “ — Equity Incentive Compensation” below. Equity Compensation Plan Information The following table sets forth information as of December 31, 2024 regarding shares of Common Stock that may be issued under our equity compensation plans. Such information includes equity compensation plans of Legacy CERo as of December 31, 2024 that were assumed by us in the Business Combination:

| Plan Category                                          |     | Number of   
 Securities  
 to be       
 Issued Upon 
 Exercise of 
 Outstanding 
 Options,    
 Warrants    
 and Rights  |       |    |     | Weighted-average 
 Exercise Price   
 of Outstanding   
 Options,         
 Warrants,        
 Rights           |        |    |     | Number of     
 Securities    
 Remaining     
 Available for 
 Future        
 Issuance      
 Under Equity  
 Compensation  
 Plans         |        |
|:-------------------------------------------------------|:----|:------------|------:|---:|:----|:-----------------|-------:|---:|:----|:--------------|-------:|
| Equity compensation plans approved by stockholders     |     |             | 3,247 | -1 |     | $                | 200.00 | -2 |     |               | 20,704 |
| Equity compensation plans not approved by stockholders |     |             |     — |    |     |                  |      — |    |     |               |